Semaglutide significantly reduced the risk of MACE by 20% in individuals with CVD + obesity
11 Jul 2025
In the large multicentre, double-blind, placebo-controlled SELECT trial, semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACE) by 20 percent in individuals with cardiovascular disease (CVD) and obesity. The MACE curves separated early before maximal weight loss, suggesting CV benefits beyond weight reduction.
Resources
Semaglutide significantly reduced the risk of MACE by 20% in individuals with CVD + obesity
Semaglutide significantly reduced the risk of MACE by 20% in individuals with CVD + obesity